Comprehensive search ChatGPT Online Scientific research tools Facebook Group Tools Telegram
Sign in Sign Up

Science Hub 每 Free Research Papers | Academic Community


[Elsevier] Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study

eraswr Post time Half hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-09-09 19:18
Reward20points

Edited by eraswr at 2026-9-6 19:19

Chao Liu 1, Qi Jia 1, Haifeng Wei 1, Xinghai Yang 1, Tielong Liu 1, Jian Zhao 1, Yan Ling 2, Chenguang Wang 3, Hongyu Yu 4, Zhenxi Li 1, Jian Jiao 1, Zhipeng Wu 1, Cheng Yang 1, Jianru Xiao 5Background: No standard treatment exists for advanced chordoma. Apatinib has been found to have promising efficacy and manageable adverse effects for the treatment of solid tumours. We aimed to investigate the safety and antitumour activity of apatinib in patients with advanced chordoma.
Methods: We did a single-arm, phase 2 study at one tertiary hospital in Shanghai, China. Eligible patients were aged 18-75 years, with histologically confirmed advanced chordoma that was unresectable or resectable only through demolitive surgery, who had previously received surgical treatment, with at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, evidence of tumour progression on enhanced CT or MRI in the previous 6 months, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received oral 500 mg apatinib once daily until disease progression or unacceptable toxicity. The co-primary endpoints were progression-free survival and objective response rate according to RECIST 1.1 and Choi criteria by investigator assessment. Progression-free survival was assessed in the intention-to-treat population. Objective response rate was assessed in the per-protocol population, which included all enrolled patients who were compliant with the protocol and had at least one post-baseline assessment. Safety was analysed in all patients with complete safety data. This study is ongoing, but recruitment is complete. This study is registered with Chictr.org.cn, ChiCTR-OIC-17013586.

You can support us by donating, we would be very grateful.
Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

Advanced Mode
B Color Image Link Quote Code Smilies
You have to log in before you can reply Login | Register

Points Rules

eraswr Lv.4
Senior Member

  • post

  • reply

  • points

    920

Same Category


Latest Reply

Announcement

Daily Top Contributors

Return to the list